Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06380335

Study in Patients With Decompensated Liver Cirrhosis

A Multicentre, Observational Study in Patients With Liver Cirrhosis Who Have Hepatic Decompensation (OPAL)

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
24 (estimated)
Sponsor
Resolution Therapeutics Limited · Network
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

OPAL is a multicenter observational study, following the natural disease trajectory of participants who have permanent damage to their liver caused by scarring, sometimes also referred to as liver cirrhosis. These participants will also have recently had an acute worsening of their liver disease, which is also known as a hepatic decompensating event, which has resulted in them being admitted to hospital or required them to seek medical attention as an outpatient.

Detailed description

This multicenter, observational natural history study is designed to follow the disease trajectory of adults with cirrhosis of the liver who have a qualifying hepatic decompensation event. The primary objective of the study is to obtain real world data to understand the clinical course of cirrhotic patients following a decompensation event in order to generate data to provide context for the safety and efficacy evaluation of future interventional treatments. Observed data will be collected from the visits and assessments conducted as part of the routine standard of care (SOC) follow-up of these patients. In addition, given the variability in SOC and timing of follow-up visits across institutions, if study required assessments do not coincide with a routine SOC visit at the institution, blood draws and other study-specific assessments will be collected at defined time points for the study analysis. All participants who meet the eligibility criteria and stabilize following a hepatic decompensation event will have their clinical course followed for up to 96 weeks, and then be invited to participate in the study long term follow observational phase for a further 3 years.

Conditions

Timeline

Start date
2023-10-10
Primary completion
2030-04-03
Completion
2030-04-03
First posted
2024-04-23
Last updated
2026-01-29

Locations

12 sites across 2 countries: Spain, United Kingdom

Source: ClinicalTrials.gov record NCT06380335. Inclusion in this directory is not an endorsement.